Drug Profile
JTR 161
Alternative Names: JR 161; JTR-161Latest Information Update: 04 Jul 2022
Price :
$50
*
At a glance
- Originator JCR Pharmaceuticals
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cerebral infarction
Most Recent Events
- 16 Mar 2021 Phase I/II development in Cerebral infarction is still ongoing in Japan (IV) (JCR Pharmaceuticals' pipeline, March 2021)
- 06 Feb 2019 Teijin and JCR Pharmaceuticals plans to launch JTR 161 for Cerebral infarction
- 30 Jan 2019 Phase-I/II clinical trials in Cerebral infarction in Japan (IV) (NCT04608838)